AKTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.6M
-70.8%
15.8M
+388.3%
3.2M
-56.4%
7.4M
+137.4%
3.1M
R&D
2.1M
+42.4%
1.5M
+34.3%
1.1M
+336.1%
249.0K
-62.7%
667.0K
SG&A
2.5M
+16.4%
2.2M
+1.3%
2.1M
+8.4%
2.0M
-19.5%
2.5M
Operating Income
-4602000
+70.8%
-15758000
-388.3%
-3227000
+56.4%
-7404000
-137.4%
-3119000
EBITDA
-4602000
-26.8%
-3628000
-12.4%
-3227000
-45.1%
-2224000
+28.7%
-3119000
Net Income
-4807000
+66.7%
-14455000
-172.8%
-5298000
+17.2%
-6400000
-237.7%
-1895000
EPS (Basic)
$0.00
$0.00
$0.00
$0.00
$0.00
EPS (Diluted)
$0.00
$0.00
$0.00
$0.00
$0.00
Shares (Diluted)
143.3B
+20.7%
118.8B
+5394.6%
2.2B
+32.3%
1.6B
-97.4%
62.9B
Akari Therapeutics plc (0.01 USD) (AKTX) โ€” Financials